Evolus (NASDAQ:EOLS) Rating Lowered to Hold at Wall Street Zen

Evolus (NASDAQ:EOLS) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other equities analysts have also recently weighed in on EOLS. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a report on Wednesday, March 4th. Stifel Nicolaus dropped their target price on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Finally, Mizuho set a $15.00 price target on Evolus in a research report on Wednesday, February 4th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Trading Up 0.6%

Shares of EOLS opened at $5.04 on Friday. Evolus has a 12 month low of $4.09 and a 12 month high of $13.66. The firm has a fifty day simple moving average of $4.87 and a 200 day simple moving average of $6.11. The stock has a market capitalization of $327.90 million, a price-to-earnings ratio of -6.22 and a beta of 1.02.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.09). The business had revenue of $90.30 million for the quarter, compared to analysts’ expectations of $89.58 million. As a group, research analysts predict that Evolus will post -0.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total transaction of $75,353.85. Following the transaction, the insider directly owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently bought and sold shares of EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after purchasing an additional 1,838 shares during the period. Millennium Management LLC raised its stake in Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after buying an additional 23,605 shares during the period. Jones Financial Companies Lllp acquired a new stake in shares of Evolus in the first quarter valued at approximately $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Evolus by 36.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after buying an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of Evolus by 484.8% during the 1st quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock worth $841,000 after acquiring an additional 57,987 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.